Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 8/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274817 | 0.95 | NPC1 (0.47) | NPC1RAB9AGSK3BMAPTTP53 | |
| SCHEMBL3277980 | 0.92 | NPC1 (0.42) | NPC1RAB9AGSK3BKDRTEK | |
| SCHEMBL3274941 | 0.89 | GSK3B (0.51) | NPC1RAB9AGSK3BMAPTCYP2D6 | |
| SCHEMBL3280340 | 0.87 | GSK3B (0.42) | GSK3BMAPTTP53CNR2CYP2D6 | |
| SCHEMBL3275205 | 0.83 | GSK3B (0.41) | NPC1RAB9AGSK3BMAPTTP53 | |
| SCHEMBL3278108 | 0.83 | GSK3B (0.44) | GSK3BCNR2CYP2D6CYP1A2 | |
| SCHEMBL3274431 | 0.82 | NPSR1 (0.44) | GSK3BCNR2CYP2D6CYP1A2 | |
| SCHEMBL3275008 | 0.82 | RECQL (0.44) | GSK3BTP53CYP2D6CYP1A2 | |
| SCHEMBL3274308 | 0.82 | HTR4 (0.48) | RAB9AGSK3BCYP2D6CYP1A2 | |
| SCHEMBL3273802 | 0.81 | TP53 (0.40) | GSK3BMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | claimed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, HPRT1, XDH | NPC1 695/4885RAB9A 2039/4885GSK3B 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.